SABRIL VS CARBAMAZEPINE MONOTHERAPY IN NONREFRACTORY COMPLEX PARTIAL SEIZURES

SABRIL 与卡马西平单一疗法治疗非难治性复杂性部分性癫痫发作

• 批准号: 6115714
• 负责人: KATHERINE HENRY
• 金额: $ 2.31万
• 依托单位: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/6115714
• 关键词: anticonvulsants; brain disorder chemotherapy; carbamazepine; clinical research; clinical trials; combination chemotherapy; drug screening /evaluation; human subject; human therapy evaluation; partial seizure

This multicenter, randomized, double-blind, placebo-controlled trial will determine the efficacy of Sabril (vigabatrin) as add-on therapy in non-refractory patients who experience occasional complex partial seizures while on carbamazepine monotherapy. The efficacy, safety and impact on quality of life of rational polytherapy with Sabril and carbamazepine.

这项多中心、随机、双盲、安慰剂对照试验 将确定Sabril(Vigabatrin)作为辅助治疗的疗效 非顽固性患者，偶尔经历复杂的部分 在接受卡马西平单一治疗时癫痫发作。疗效、安全性和安全性 沙培林和安慰剂合理综合治疗对患者生活质量的影响 卡马西平。